Tandem Diabetes rises after rival flags strong demand

Tandem Diabetes Care

10/05/2024 16:38

** Shares of Tandem Diabetes Care  TNDM.O  up 2.81% at
$45.29 after rival Insulet Corp  PODD.O  raises FY rev growth
forecast 
    ** Insulet raises its annual revenue growth forecast,
banking on strong sales of its wearable, tubeless insulin pumps
    ** PODD now sees FY rev growth of 14%-18% vs. 12%-17% growth
expected earlier and above analysts' average estimates of
15.62%, according to LSEG data
    ** Earlier in May TNDM had also raised its FY adj sales
forecast to $868 mln from $850 mln
    ** TNDM up about 52.65% YTD

 (Reporting by Vaibhav Sadhamta)
 ((Vaibhav.Sadhamta@thomsonreuters.com;))